top
Please input keywords
Download Our AACR2024 Posters!
2024.04.16



We are thrilled to have had the opportunity to attend the American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, CA. Your interest in our research progress and the insightful discussions we had about your projects and objectives truly made our experience at AACR memorable. These exchanges are invaluable in advancing our collective efforts in cancer research.

We presented 20 posters including 9 antibody-based drug assets, 10 genetically engineered mouse models and 1 preclinical pharmacology study. Below, you will find all of the poster presentations from the conference available for download!



Modality

Abstract Number

Poster Title

mAb

LB130

Identification of fully human CCR8 antibodies that demonstrate excellent ADCC function, potent blocking activity, and robust anti-tumor immune responses

TCRm

6717

Targeting mutant KRAS proteins with novel TCR-mimic fully human antibodies

bsAb

2724

BCG020, a novel bispecific antibody targeting EGFR and CD70, is effective against EGFR and CD70 high expressed tumors

bsADC

2620

BCG016, a first-in-class bispecific antibody-drug conjugate targeting 5T4 and MUC1, demonstrates potent preclinical anti-tumor activity

2618

BCG017, a bispecific ADC targeting PTK7 and EGFR exhibits anti-tumor efficacy in PDX models

2619

A novel EGFR×HER3-targeting bispecific antibody drug-conjugate, BCG019, demonstrates robust anti-tumor efficacy in preclinical evaluation

2617

BCG022, a novel HER3×MET bispecific antibody-drug conjugate (bsADC), demonstrates promising anti-tumor efficacy

LB127

A first-in-class bispecific ADC targeting FOLR1 and MUC1 exhibits promising anti-tumor activity in a FOLR1low xenograft model

2616

BCG033, a novel bispecific antibody-drug conjugate targeting PTK7 and TROP2, demonstrates preclinical efficacy against triple-negative breast cancer and other solid tumor xenografts


Abstract Number

Model(s)

Poster Title

113

B-hIL31/hIL31RA/hOSM/hOSMR mice

Generation and validation of a novel humanized IL-31/IL-31RA/OSM/OSMR mouse model

116

B-hPD-1/hPD-L1/hCD94/hNKG2A mice

Generation of humanized PD-1/PD-L1/CD94/NKG2A mice for evaluating novel combination therapies

123

B-hCD3EDG/h4-1BB mice

Establishment of humanized CD3EDG/4-1BB mice for testing novel T cell engagers

124

B-hTL1A mice

Validation of humanized TL1A mice for advancing preclinical research

125

B-hVEGFA mice

Development of humanized VEGFA models to assess preclinical efficacy of novel therapeutics in vivo

5339

B-hIL5/hIL5RA mice

Establishment of a humanized IL5/IL5RA mouse model to evaluate modulators of eosinophilic inflammation in vivo

5345



Development and validation of humanized HLA mouse model platforms for preclinical evaluation of novel peptide vaccines

5346

B-hCD16A (CB-17 SCID) mice

A novel humanized CD16A model to evaluate efficacy of human antibody therapeutics in triggering ADCC

LB363

B-hNKP46 mice

A novel humanized NKP46 mouse model to support xenograft studies evaluating NK cell-based cancer immunotherapies

LB365

B-SDG rats

Generation of a novel severely immunodeficient Sprague Dawley rat model for xenograft studies

1531



TIL analysis demonstrates different mechanisms underlying PD-1 resistance in animal models



Want to discuss parnership opportunities for our drug assets, fully human antibody discovery RenMice® platforms, mouse models, or preclinical pharmacology services? Contact us today!


Contact Us